Feature | January 23, 2014

Nanotherapy Advancement May Help Reduce Recurrent Heart Attacks and Stroke

HDL nanoparticle delivers statin medication to inflamed blood vessels, prevents repeat heart attacks, stroke

January 23, 2014 — Up to 30 percent of heart attack patients suffer an additional heart attack because of limited ability to control inflammation inside heart arteries that leads to clots rupturing and myocardial infarction or stroke.
 
An international research team, led by Icahn School of Medicine at Mount Sinai investigators, designed and tested a high-density lipoprotein (HDL) nanoparticle loaded with a statin drug. In mouse studies, they show HDL nanotherapy is capable of directly targeting and lowering dangerous inflammation in blood vessels.
 
HDL nanotherapy could potentially avert repeat heart attacks and may also reduce recurrent strokes caused by clots in brain arteries. 
 
The nanoparticles resemble HDL cholesterol particles and bind to the same receptors as natural HDL in order to deliver the statin drug. Oral statin medications work primarily in the liver to reduce levels of unhealthy lipids circulating in the blood. Statins also exert a very weak dampening effect on some inflammatory cells, foremost macrophages that hide in plaque in arterial walls. Researchers sought to bolster this anti-inflammatory function in their HDL nanotherapy design.
 
 “Levels of inflammation spike after a heart attack, which is why up to 30 percent of heart attack patients may suffer another heart attack, some while in hospital or just after discharge,” said co-author Zahi Fayad, Ph.D., professor of radiology and director of the Translational and Molecular Imaging Institute at Icahn.
 
According to Mount Sinai researchers, the best way to use their HDL nanotherapy is by injection after the clot that produces a heart attack or stroke has been treated. The HDL nanoparticle would deliver the statin directly to macrophages that are driving the inflammatory response.
“Our study also confirms that the HDL nanoparticle is not seen as a foreign invader by the body’s immune system and that it has an inherent and natural affinity to target plaque macrophages,” said first author Jun Tang, Ph.D, M.S.
 
The team intends to conduct a clinical trial to test the HDL nanotherapy on humans. 
 
For more information: www.mountsinai.org

Related Content

BioCardia Announces 12-Month Results from TRIDENT Trial of Stem Cell Delivery System
News | Stem Cell Therapies| September 26, 2017
BioCardia Inc. recently announced 12-month results from the Phase II TRIDENT clinical trial, conducted by the...
News | Vena Cava Filters| September 26, 2017
September 26, 2017 — The one-year results of the SENTRY...
Treatment of Heart Attack Patients Depends on Cancer History
News | Cardio-oncology| September 26, 2017
Treatment of heart attack patients depends on their history of cancer, according to research published recently in...
CardiAMP Heart Failure Trial Design Presented at Texas Heart Institute Symposium
News | Heart Failure| September 25, 2017
BioCardia Inc. announced the trial design for its pivotal Phase III CardiAMP Heart Failure Trial was presented during...
Biotronik Studies Demonstrate Efficacy of Minimizing Metal Burden in SFA Therapy
News | Stents Bare Metal| September 22, 2017
Physicians demonstrated that reducing metal burden in superficial femoral artery (SFA) therapy could effectively reduce...
Edwards Inspiris Resilia Valve Receives FDA Approval
News | Heart Valve Technology| September 21, 2017
Edwards Lifesciences Corp. recently received U.S. Food and Drug Administration (FDA) approval for its Inspiris Resilia...
MyoKardia Presents Additional Positive Data From Phase 2 PIONEER-HCM Study at HFSA 2017
News | Heart Failure| September 21, 2017
MyoKardia Inc. announced that additional positive data from the first patient cohort of its Phase 2 PIONEER-HCM study...
Tryton Side Branch Stent Recognized With Premier Technology Breakthrough Award
News | Stents Bifurcation| September 21, 2017
September 21, 2017 — Cardinal Health and Tryton Medical Inc.
DISRUPT BTK Study Shows Positive Results With Lithoplasty in Calcified Lesions Below the Knee
News | Peripheral Artery Disease (PAD)| September 20, 2017
Shockwave Medical reported positive results from the DISRUPT BTK Study, which were presented at the annual...
Corindus Announces First Patient Enrolled in PRECISION GRX Registry
News | Robotic Systems| September 18, 2017
September 18, 2017 — Corindus Vascular Robotics Inc.
Overlay Init